Posted by Michael Wonder on 15 Apr 2026
Praxis Precision Medicines announces FDA acceptance of new drug application for ulixacaltamide hydrochloride in patients with essential tremor
14 April 2026 - - Praxis Precision Medicines today announced that the US FDA has accepted for review its new drug application for ulixacaltamide hydrochloride for the treatment of essential tremor in adults.
The FDA has set a target action date under the PDUFA of 29 January 2027 and is not planning to hold an advisory committee meeting.
